New immune therapy takes on virus-driven blood cancers in tiny early trial
NCT ID NCT05635591
First seen Apr 09, 2026 · Last updated May 20, 2026 · Updated 7 times
Summary
This early study tests a new treatment called KSD-101 in 9 people with blood cancers linked to the Epstein-Barr virus. The main goal is to see if the treatment is safe and to find the best dose. Participants have cancers that did not respond to standard treatments. The study will also check if the treatment can shrink tumors or control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-ASSOCIATED HAEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Li Chunrui
Wuhan, Hubei, 430000, China
Conditions
Explore the condition pages connected to this study.